A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05743621

Title field or adapter rule

{'original_value': 'A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:06.681676+00:00

Published At

2026-10-26T00:00:00+00:00

Record Updated At

2026-10-26

Source Retrieved At

2026-11-01T01:03:05.968908+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Prostatic Neoplasms, Castration-Resistant"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-26", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05743621"

protocolSection.identificationModule.officialTitle

"A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination With Enzalutamide (Xtandi) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Prostatic Neoplasms, Castration-Resistant (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['TVB-2640 in combination with Enzalutamide'], 'description': 'TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol', 'name': 'TVB-2640', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['TVB-2640 in combination with Enzalutamide'], 'description': '160 mg daily PO', 'name': 'Enzalutamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• TVB-2640 (protocolSection.armsInterventionsModule.interventions[].name)
• Enzalutamide (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.